Biodesix, Inc.

205 articles about Biodesix, Inc.

• Biodesix Pipeline Test Identifies Patients Who Are Likely to Respond to Immune Checkpoint Inhibitors

  7/16/2020

  Biodesix, Inc., a leader in lung cancer diagnostics, announced the publication of research findings on a diagnostic test capable of generating valuable data to help guide the treatment of patients with advanced non-small cell lung cancer.

• Major League Lacrosse Partners with Biodesix

  7/13/2020

  Major League Lacrosse (MLL) today announced a partnership with Biodesix, Inc., whereby Biodesix will be the exclusive provider of COVID-19 testing for the upcoming 2020 MLL season.

• Biodesix Launches COVID-19 WorkSafe™ Employer Testing Program

  6/8/2020

  Range of Testing Solutions Aimed at Helping Businesses Safely Resume Work Operations

• Biodesix Presents Numerous Research Findings at ATS, ASCO, and AACR Virtual Conferences

  5/27/2020

  Clinical Data Offer Meaningful Diagnostic Information for Patients in the Lung Cancer Continuum of Care

• Biodesix Partners with Boulder Community Health to Expand Access to COVID-19 Testing

  5/20/2020

  Biodesix, Inc., a leading diagnostic company in lung disease, announced that it has partnered with Boulder Community Health, a community owned-and-operated not-for-profit health system, to offer expanded COVID-19 testing in the greater Boulder, CO area.

• Biodesix Collaborates With Bio-Rad to Launch a Serology Test to Detect Coronavirus (COVID-19) Antibodies

  5/19/2020

  Biodesix, Inc., a leading diagnostic company in lung disease, announced that it has collaborated with Bio-Rad Laboratories, Inc. to launch a blood-based immunoassay-based test that identifies antibodies to SARS-CoV-2, the virus that causes COVID-19.

• Biodesix Begins Coronavirus COVID-19 Testing

  4/8/2020

  Droplet Digital™ PCR Test Offered for Detection of SARS-CoV-2

• Biodesix Partners with Bio-Rad to Bring Emergency Use Authorization (EUA) COVID-19 ddPCR™ Test to the U.S.

  3/20/2020

  Data show Droplet Digital™ PCR Test Can Detect COVID-19 with Greater Sensitivity and Precision

• Biodesix Announces New Commercial Organization and Executive Appointments

  3/10/2020

  New Structure Increases Customer Focus, Agility and Growth Opportunities

• Biodesix Strengthens Lung Nodule Testing Strategy with the Nodify CDT™ Test

  3/3/2020

  Biodesix, Inc. a leader in lung cancer diagnostics, is extending its blood-based testing portfolio with the release of the Nodify CDTTM test, designed to help physicians identify patients with lung nodules at high risk of lung cancer.

• Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc.

  2/11/2020

  Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY.

• Biodesix Partners with Streck to Support In Vitro Diagnostic (IVD) Strategy

  1/29/2020

  Biodesix, Inc. and Streck, Inc. today announced a Regulatory Cooperation Agreement that will further enable both companies in their pursuit of FDA approval for diagnostic testing services and specimen collection products.

• AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

  1/27/2020

  AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).

• Biodesix Named Company of the Year by Colorado BioScience Association

  11/8/2019

  Biodesix, Inc. has been named Company of the Year by the Colorado BioScience Association (CBSA). The company was honored at the 16th Annual CBSA Awards Dinner on November 7, 2019.

• AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML

  11/7/2019

  AVEO Oncology and Biodesix, Inc. announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia.

• Biodesix Appoints Scott Hutton as Chief Executive Officer

  11/5/2019

  Former CEO David Brunel to Serve as Chairman of the Board of Directors

• Biodesix Announces First System-Wide Integration of Nodify XL2 Testing for Lung Nodule Management

  11/4/2019

  Biodesix, Inc. the leader in lung cancer diagnostics, today announced that Tri-Star Health in Nashville, TN, the region's largest, most comprehensive healthcare provider, is the first hospital system in the U.S. to adopt the recently launched Nodify XL2™ proteomic nodule classifier for incidental lung nodule management. 1.6 million lung nodules are detected incidentally each year in the U.S., but fewer than five percent turn out to be malignan

• Biodesix Completes Acquisition of Oncimmune Assets in the United States

  11/1/2019

  Biodesix, Inc., today announced that it has completed acquisition of Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the United States, further extending the company’s blood-based lung cancer diagnostic portfolio

• Biodesix Names Dr. James Jett Chief Medical Officer

  10/8/2019

  Biodesix, Inc. the leader in lung cancer diagnostics, today announced the appointment of internationally recognized lung cancer expert, James Jett, M.D., as Chief Medical Officer

• Biodesix Secures U.S. Patent for Proprietary Blood Specimen Collection Device

  10/3/2019

  Innovative New Device Enhances Ease of Use and Reduces Cost and Environmental Impact of Blood Sample Collection, Processing, and Shipping